By
/topics.wsj.com/person/G/charley-grant/8446","text":"Biography"},{"type":"link","icon":"twitter","url":"https://twitter.com/CGrantWSJ","text":"@CGrantWSJ"},{"type":"link","icon":"email","url":"mailto:charles.grant@wsj.com","text":"charles.grant@wsj.com"}]}" itemprop="author" itemscope="" itemtype="https://schema.org/Person" style="margin: 0px; padding: 0px; border: 0px; outline: 0px; vertical-align: baseline; display: inline-block; color: rgb(102, 102, 102); position: inherit; background-position: 0px 0px;"> CHARLEY GRANT
At publicly traded companies, “success” takes many forms.
Lead independent director Jordan Kupinsky said in a statement that the company “looks forward to building on our past successes,” citing a portfolio of over 200 products and “opportunities for organic growth” among them.
That reference to past success might leave shareholders confused: Shares are down more than 88% this year as the embattled drug manufacturer grapples with scrutiny from payers over its high drug prices and a significant debt burden.
As if that weren’t enough, the end of Mr. Thompson’s tenure was marked by controversy. He sued the short seller Marc Cohodes for libel this summer after the investor criticized the CEO’s tenure at another drug company. Shortly after that lawsuit was filed, Mr. Thompson was forced to sell more than half a million shares following a margin call.